Drug Profile
Diatomic iodine
Latest Information Update: 27 Jul 1999
Price :
$50
*
At a glance
- Originator Mimetix
- Developer Mimetix; Sanofi-Synthelabo
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Fibrocystic breast disorders
Most Recent Events
- 27 Jul 1999 No-Development-Reported for Fibrocystic breast disorders in Canada (PO)
- 27 Jul 1999 No-Development-Reported for Fibrocystic breast disorders in USA (PO)
- 27 Feb 1997 Phase-III clinical trials for Fibrocystic breast disorders in Canada (PO)